Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T59679 | ||||
Target Name | 5-HT 4 receptor (HTR4) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Tegaserod | Drug Info | EC50 ~= 5 nM | ||
1-((S)-2-aminopropyl)-1H-indazol-6-ol | Drug Info | Ki = 515 nM | [1] | ||
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | Ki < 1000 nM | [5] | ||
BARETTIN | Drug Info | Ki = 1910 nM | [2] | ||
GR-113808 | Drug Info | Ki = 0.7 nM | [3] | ||
Norcisapride | Drug Info | IC50 = 19 nM | [4] | ||
SB-207710 | Drug Info | Ki = 2.2 nM | [6] | ||
SEROTONIN | Drug Info | Ki = 500 nM | [2] | ||
Action against Disease Model | Tegaserod | Drug Info | EC50 on Afferent nerve activity to rectal distension in cats: 700000ng/kg | ||
References | |||||
REF 1 | 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. | ||||
REF 2 | Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4. | ||||
REF 3 | Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers. J Med Chem. 2007 Sep 6;50(18):4482-92. | ||||
REF 4 | mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83. | ||||
REF 5 | Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. | ||||
REF 6 | Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for ... J Med Chem. 2010 Oct 14;53(19):7035-47. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.